117 related articles for article (PubMed ID: 38696842)
1. Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer.
Jiang Z; Zhu M; Zhang L; Cui H; Jiang R; Yang Y
Gynecol Oncol; 2024 Apr; 187():1-11. PubMed ID: 38696842
[TBL] [Abstract][Full Text] [Related]
2. Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy.
Zhu M; Zhang L; Cui H; Zhao Q; Wang H; Zhai B; Jiang R; Jiang Z
Front Immunol; 2021; 12():800951. PubMed ID: 35069585
[TBL] [Abstract][Full Text] [Related]
3. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors.
He Z; Feng W; Wang Y; Shi L; Gong Y; Shi Y; Shen S; Huang H
Transl Lung Cancer Res; 2023 Mar; 12(3):510-529. PubMed ID: 37057124
[TBL] [Abstract][Full Text] [Related]
4. FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer.
Guo Z; Yan X; Song C; Wang Q; Wang Y; Liu XP; Huang J; Li S; Hu W
Front Oncol; 2021; 11():603660. PubMed ID: 33816234
[TBL] [Abstract][Full Text] [Related]
5. LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma.
Liu F; Hou W; Liang J; Zhu L; Luo C
J Cancer; 2021; 12(13):4039-4048. PubMed ID: 34093808
[TBL] [Abstract][Full Text] [Related]
6. LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment.
Cheng Y; Tang R; Li X; Wang B; Cheng Y; Xiao S; Sun P; Yu W; Li C; Lin X; Zhu Y
J Hepatocell Carcinoma; 2022; 9():203-220. PubMed ID: 35345553
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma.
Xu J; Shen X; Zhang B; Su R; Cui M; Yan L; Cao Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34386813
[TBL] [Abstract][Full Text] [Related]
8. Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.
Dai Y; Zhao L; Hua D; Cui L; Zhang X; Kang N; Qu L; Li L; Li H; Shen D; Wang Z; Wang J
Front Immunol; 2022; 13():1035616. PubMed ID: 36532042
[TBL] [Abstract][Full Text] [Related]
9. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
[No Abstract] [Full Text] [Related]
10. Potential predictive value of comutant LRP1B and FAT for immune response in non-small cell lung cancer: LRP1B and FAT comutation enhance immune response.
Hao F; Ma Q; Zhong D
Transl Oncol; 2022 Oct; 24():101493. PubMed ID: 35905642
[TBL] [Abstract][Full Text] [Related]
11. TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy.
Yu J; Fan Z; Zhou Z; Zhang P; Bai J; Li X; Tang M; Fan N; Wu X; Nie X; Chen X; Ma D; Chen X; Cui L; Xia X; Yang L; Yi X; Li L
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884443
[TBL] [Abstract][Full Text] [Related]
12.
Brown LC; Tucker MD; Sedhom R; Schwartz EB; Zhu J; Kao C; Labriola MK; Gupta RT; Marin D; Wu Y; Gupta S; Zhang T; Harrison MR; George DJ; Alva A; Antonarakis ES; Armstrong AJ
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653800
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Implications of LRP1B and Its Relationship with the Tumor-Infiltrating Immune Cells in Gastric Cancer.
Wang R; Zhang G; Zhu X; Xu Y; Cao N; Li Z; Han C; Qin M; Shen Y; Dong J; Ma F; Zhao A
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136305
[TBL] [Abstract][Full Text] [Related]
14. Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation.
Wang T; Yu D; Wang J; Zhu N; Tang XB; Chen X; Su XM; Huang YG
Front Oncol; 2023; 13():1250558. PubMed ID: 38023184
[TBL] [Abstract][Full Text] [Related]
15. Correlation between
Hu S; Zhao X; Qian F; Jin C; Hou K
Comput Math Methods Med; 2021; 2021():1522250. PubMed ID: 34603481
[TBL] [Abstract][Full Text] [Related]
16. Prognostic biomarkers correlated with immune infiltration in non-small cell lung cancer.
Xu F; Cui WQ; Liu C; Feng F; Liu R; Zhang J; Sun CG
FEBS Open Bio; 2023 Jan; 13(1):72-88. PubMed ID: 36282125
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients.
Liu B; Dong Z; Lu Y; Ma J; Ma Z; Wang H
Evid Based Complement Alternat Med; 2022; 2022():3478861. PubMed ID: 36034941
[TBL] [Abstract][Full Text] [Related]
18. The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma.
Wang M; Xiong Z
Int J Gen Med; 2021; 14():6343-6358. PubMed ID: 34629898
[TBL] [Abstract][Full Text] [Related]
19. LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma.
Yu G; Mu H; Fang F; Zhou H; Li H; Wu Q; Xiong Q; Cui Y
Medicine (Baltimore); 2022 Jul; 101(26):e29763. PubMed ID: 35777027
[TBL] [Abstract][Full Text] [Related]
20. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
